Phosphate wasting and fibroblast growth factor-23

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 6, 2013, Pages 523-531

  Nanes, Mark S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibroblast growth factor 23; Fracture; Osteomalacia; Phosphate; Phosphaturia; Rickets

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IRON; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DRUG MEGADOSE; FEEDBACK SYSTEM; HUMAN; HYPOPHOSPHATEMIA; INTESTINE ABSORPTION; IRON DEFICIENCY; KIDNEY FAILURE; MALABSORPTION; MUSCLE STRENGTH; NEGATIVE FEEDBACK; NONHUMAN; ONCOGENIC OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PHOSPHATURIA; REVIEW; RICKETS; SENSOR;

BONE AND BONES; CARDIOVASCULAR DISEASES; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; OSTEOMALACIA; PHOSPHATES; VITAMIN D DEFICIENCY;

EID: 84890129716     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/01.med.0000436189.80104.80     Document Type: Review

References (43)

1. Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012; 8:276-286.
2. Bergwitz C, Juppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol 2012; 728:41-64.
3. Hansen KaDM. Clinical disorders of phosphate homeostasis. In: Feldman DPJ, Adams J, editors. Vitamin D. 3. Waltham, MA: Elsevier; 2011. pp. 1155-1186.
4. Prader A, Illig R, Uehlinger E, Stalder G. Rickets following bone tumor. Helv Paediatr Acta 1959; 14:554-565.
5. Meyer RA Jr, Tenenhouse HS, Meyer MH, Klugerman AH. The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy. J Bone Miner Res 1989; 4:523-532.
6. Cai Q, Hodgson SF, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 1994; 330:1645-1649.
7. White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001; 86:497-500.
8. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079-2086.
9. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001; 98:6500-6505.
10. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87:4957-4960.
11. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656-1663.
12. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Ann Rev Physiol 2007; 69:341-359.
13. Cavalli L, Mazzotta C, Brandi ML. Phosphatonins: physiological role and pathological changes. Clin Cases Miner Bone Metab 2012; 9:9-12.
14. Wohrle S, Henninger C, Bonny O, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23- mediated hypophosphatemic rickets. J Bone Miner Res 2013; 28:899-911.
15. Martin A, Liu S, David V, et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011; 25:2551-2562.
16. Mackenzie NC, Zhu D, Milne EM, et al. Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice. PLoS One 2012; 7:e32177.
17. Benet-Pages A, Lorenz-Depiereux B, Zischka H, et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004; 35:455-462.
18. Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 2008; 105:3455-3460.
19. McAnce RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med 1947; 16:33-46.
20. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer 2011; 18:R53-R77.
21. Chong WH, Andreopoulou P, Chen CC, et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Mineral Res 2013; 28:1386-1398. Chong et al. [21] describe their unique experience with a large cohort of patients with oncogenic osteomalacia and the diagnostic utility of imaging modalities for FGF-23 producing tumor localization.
22. Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004; 89:3979-3982.
23. van Boekel G, Ruinemans-Koerts J, Joosten F, et al. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol 2008; 158:431-437.
24. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia- associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004; 28:1-30.
25. Juppner H. Phosphate and FGF-23. Kidney Int 2011; 79 (Suppl 121):S24-S27.
26. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82:737-747.
27. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592.
28. Seiler S, Reichart B, Roth D, et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25:3983-3989.
29. McCance RA. Quarterly J Med 1947; 16:33-46.
30. Arnlov J, Carlsson AC, Sundstrom J, et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013; 8:781-786. Arnlov showed a prospective relationship between FGF-23 and cardiovascular outcomes in community-dwelling seniors including those without CKD.
31. Masai H, Joki N, Sugi K, Moroi M. A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease. Atherosclerosis 2013; 226:228-233.
32. Coen G, De Paolis P, Ballanti P, et al. Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol 2011; 24:313-321.
33. Khan AM, Chirinos JA, Litt H, et al. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol 2012; 7:2017-2022.
34. Srivaths PR, Goldstein SL, Silverstein DM, et al. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011; 26:945-951.
35. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
36. Smith K, deFilippi C, Isakova T, et al. Fibroblast growth factor 23, highsensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Am J Kidney Dis 2013; 61:67-73.
37. Braithwaite V, Jarjou LM, Goldberg GR, Prentice A. Iron status and fibroblast growth factor-23 in Gambian children. Bone 2012; 50:1351-1356.
38. Imel EA, Peacock M, Gray AK, et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011; 96:3541-3549.
39. Schouten BJ, Hunt PJ, Livesey JH, et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009; 94:2332-2337.
40. Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009; 45:814-816.
41. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011; 108:E1146-E1155.
42. Deger SM, Erten Y, Pasaoglu OT, et al. The effects of iron on FGF23- mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 2013; 17:416-423.
43. Takeda Y, Komaba H, Goto S, et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011; 33:421-426.